Skip to main content

Part of the book series: Yearbook of Intensive Care and Emergency Medicine ((YEARBOOK,volume 1997))

Abstract

Patients in intensive care units (ICU) have a variety of complex problems, often with multiple-organ dysfunction, putting them at an exceptionally high risk of adverse drug reactions because of alteration of usual pathways for drug metabolism and excretion. Prescribing for these patients is therefore very difficult since altered drug excretion, impaired metabolism, altered volumes of drug distribution, and drug interactions are problems that need to be overcome to provide safe and effective therapy. Many of these seriously ill patients acquire complications such as nosocomial infection with resultant impaired systemic hemodynamics which further compromises drug metabolism and elimination. Thus, renal failure in the ICU is an adverse prognostic feature for morbidity and mortality, whether it be part of the underlying illness, or acquired due to therapies of those illnesses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett WM, Elzinga LW, Porter GA (1991) Tubulointerstitial disease and toxic nephropathy. In: Brenner B, Rector F (eds) The Kidney. Saunders, Philadelphia, pp 1430–1496

    Google Scholar 

  2. Rush GF, Smith JH, Newton JF, Hook JB (1984) Chemically induved nephrotoxicity: Role of metabolic activation. Crit Rev Toxicol 13: 99–160

    Google Scholar 

  3. Bennett WM (1989) Mechanisms of aminoglycoside nephrotoxicity Clin Exp Pharmacol Physio116: 1–6

    Google Scholar 

  4. Moestrup SK, Cui S, Vorum H, et al (1995) Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs J Clin Invest 96: 1404–1413

    CAS  Google Scholar 

  5. Humes HD (1988) Amnioglycoside nephrotoxicity. Kidney Int 33: 900–911

    Article  PubMed  CAS  Google Scholar 

  6. Burdmann EA, Andoh TF, Lindsley J, Houghton DC, Bennett WM, Porter GA (1994) Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Renal Failure: 16: 161–168

    Article  PubMed  CAS  Google Scholar 

  7. Houghton DC, Campbell-Boswell MV, Bennett WM (1987) Myeloid bodies in the renal tubules of humans: Relationship to gentamicin therapy. Clin Nephrol 10: 140–145

    Google Scholar 

  8. Bricker NS, Patton JF (1957) Renal function studies in polycystic disease of the kidneys (with observations on the effects of surgical decompression). N Engl J Med 256: 212–214

    Article  PubMed  CAS  Google Scholar 

  9. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA (1979) The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure. J Infect Dis 140: 576–580

    Google Scholar 

  10. Barza M, Ioannidis JP, Cappelleri JC, Lau J (1996) Single or multiple daily doses of aminoglycosides: A meta-analysis. Br Med J 312: 338–345

    Google Scholar 

  11. Hatala R, Dinh T, Cook DJ (1996) Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 124: 717–725

    Google Scholar 

  12. Bult J, Franklin CM (1996) Using amphotericin B in the critically ill: A new look at an old drug. J Crit Illness 11: 577–585

    Google Scholar 

  13. Branch RA (1988) Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 148: 2389–2394

    Article  PubMed  CAS  Google Scholar 

  14. Bennett WM, Henrich WL, Stoff JS (1996) The renal effects of non-steroidal anti-inflammatory drugs: Summary and recommendations. Am J Kidney Dis 28: S56 - S62

    Article  PubMed  CAS  Google Scholar 

  15. Bennett WM (1995) The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43: S3 - S7

    PubMed  Google Scholar 

  16. Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725–1738

    Article  CAS  Google Scholar 

  17. Bierer BE, Hollander G, Fruman D, Burakoff SJ (1993) Cyclosporin A and FK506: Molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immuno15: 763–773

    Google Scholar 

  18. Textor SC, Wiesner R, Wilson DJ, et al (1993) Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 55: 1332–1339

    Article  PubMed  CAS  Google Scholar 

  19. Rudnick MR, Berns JS, Cohen RM (1996) Contrast media-associated nephrotoxity. Curr Opin Nephrol Hypertens 5: 127–133

    Article  PubMed  CAS  Google Scholar 

  20. Rudnick MR, Goldfarb S, Wexler L, et al (1995) Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: A randomized trial. Kidney Int 47: 254–261

    Google Scholar 

  21. Solomon R, Werner C, Mann D (1994) Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331: 1416–1420

    Article  PubMed  CAS  Google Scholar 

  22. Textor SC (1990) ACE inhibitors in renovascular hypertension. Cardiovasc Drugs Ther 4: 229–235

    Article  PubMed  CAS  Google Scholar 

  23. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA (1991) Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 115: 513–519

    PubMed  CAS  Google Scholar 

  24. Vogelzang NJ (1991) Nephrotoxicity from chemotherapy: Prevention and management. Oncology 5: 97–112

    PubMed  CAS  Google Scholar 

  25. Zager RA (1994) Acute renal failure in the setting of bone marrow transplantation. Kidney Int 46: 1443–1458

    Article  PubMed  CAS  Google Scholar 

  26. Stark AN, Jackson G, Carey PJ, Arfeen S, Proctor SJ (1989) Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 24: 243–245

    Article  PubMed  CAS  Google Scholar 

  27. Berns JS, Cohen RM, Stumacher RJ, Rudnick MR (1991) Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1: 1061–1080

    PubMed  CAS  Google Scholar 

  28. Becker BN, Schulman G (1996) Nephrotoxicity of antiviral therapies. Curr Opin Nephrol Hyper-tens 5: 375–379

    Article  CAS  Google Scholar 

  29. Wagstaff AJ, Bryson HM (1994) Foscarnet: A reappraisal of its antiviral activity, pharmavokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48: 199–226

    Google Scholar 

  30. Goa KL, Campoli-Richards DM (1987) Pentamidine isethionate: A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33: 242–258

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bennett, W.M. (1997). Nephrotoxic Acute Renal Dysfunction. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1997. Yearbook of Intensive Care and Emergency Medicine, vol 1997. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-13450-4_70

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-13450-4_70

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-13452-8

  • Online ISBN: 978-3-662-13450-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics